Drug Interactions of Ixazomib
Precautions for Concomitant Drug Use
Metabolic Enzyme Inhibitors
Concomitant use with strong CYP3A inhibitors (e.g., clarithromycin) results in a 4% decrease in peak drug concentration and an 11% increase in total exposure (changes do not meet dose adjustment criteria).
Concomitant use with strong CYP1A2 inhibitors does not cause significant changes in drug concentration.
No dose adjustment is required for concomitant use with either class of inhibitors.
Metabolic Enzyme Inducers
Concomitant use with strong CYP3A inducers (e.g., rifampicin) leads to a dramatic decrease in drug concentration (54% reduction in peak concentration, 74% reduction in total exposure); coadministration is contraindicated.
Effects on Other Drugs
Ixazomib does not inhibit or induce the activity of CYP metabolic enzymes, nor does it cause drug interactions via hepatic transporters.
Contraceptive Drugs
Concomitant use with dexamethasone may reduce the efficacy of hormonal contraception; barrier contraceptive methods are recommended during combined use.
Special Note
For the standard combination regimen of ixazomib, lenalidomide, and dexamethasone, special attention should be paid to referring to the full prescribing information of the other two agents.
Contraindicated Populations of Ixazomib
The following populations are explicitly contraindicated for ixazomib:
Patients with hypersensitivity to the active ingredient or any excipient in the formulation.
Women who are pregnant, breastfeeding, or planning pregnancy.
Important Reminder
Since ixazomib must be used in combination with lenalidomide and dexamethasone, the contraindications of these two agents must also be considered. Unauthorized use by the above populations may lead to severe consequences, including exacerbation of underlying diseases or life-threatening adverse reactions, and must be strictly avoided.
Populations Requiring Cautious Use of Ixazomib
Caution is advised in the following situations:
1.Driving and machinery operation: Clinical observations indicate that some patients may experience fatigue, dizziness, or other symptoms; such patients should immediately cease relevant operations.
2.Patients aged 75 years and older: Clinical data show that 28% of elderly patients receiving ixazomib discontinued treatment (vs. 16% in the placebo group). The incidence of arrhythmia was 21% in the treatment group (vs. 15% in the placebo group).
These populations may face increased health risks after use and must strictly follow medical advice. If use is necessary, preparations should include regular monitoring of physical conditions during treatment, immediate contact with a physician for any abnormal symptoms, and development of emergency plans by the medical team.
Use of Ixazomib in Special Populations
Key Population Considerations
Pregnant, breastfeeding, or planning-pregnancy women: Strictly contraindicated.
Patients aged 75 years and older: Use only after careful weighing of risks and benefits.
Patients with hepatic or renal impairment: No data on safety and efficacy are currently available.
Pediatric use: No clinical research data support this indication.
Critical Reminder
Female patients of childbearing potential should proactively inform their physician of their reproductive status during consultation to facilitate the development of an individualized treatment plan.
